✦ LIBER ✦

601 EFFICACY AND SAFETY OF PEGINTERFERON ALFA-2A 360 μG/WEEK IN COMBINATION WITH RIBAVIRIN IN HEPATITIS C GENOTYPE 1 PATIENTS WITH CIRRHOSIS: ANALYSIS FROM THE CHARIOT STUDY

✍ Scribed by W.S.C. Cheng; S. Roberts; M. Weltman; D.H.G. Crawford; W. Sievert; G. McCaughan; W. Rawlinson; P. Desmond; M. Yoshihara; B. Rizkalla; J. DePamphilis; P. Marks; G.J. Dore

Book ID: 117377610
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 53 KB
Volume: 50
Category: Article
ISSN: 0168-8278
DOI: 10.1016/s0168-8278(09)60603-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Peginterferon alfa-2a and peginterferon

Peginterferon alfa-2a and peginterferon alfa-2b combined with ribavirin in patients with genotype 1 chronic hepatitis C: Results of a prospective single-centre study

✍ Berak, Hanna; Laskus, Tomasz; Kołakowska-Rządzka, Anna; Wasilewski, Marek; Stańc 📂 Article 📅 2014 🏛 Versita 🌐 English ⚖ 276 KB

1041 EFFICACY AND SAFETY OF ALBINTERFERO

1041 EFFICACY AND SAFETY OF ALBINTERFERON ALFA-2B IN COMBINATION WITH RIBAVIRIN IN TREATMENT- NAIVE, CHRONIC HEPATITIS C GENOTYPE 1 (CHC G1) PATIENTS

✍ Zeuzem, S.; Sulkowski, M.; Lawitz, E.; Rustgi, V.; Lurie, Y.; Grigorescu, M.; Mu 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 48 KB

Safety and efficacy of combination thera

Safety and efficacy of combination therapy with peginterferon alfa-2a (40kD) and ribavirin in the outpatient setting: prospective analysis of 197 patients with chronic hepatitis C viral infection

✍ Thierry Fontanges; Sylvain Beorchia; Catherine Douvin; Patrick Delassalle; Jean- 📂 Article 📅 2007 🏛 Masson Editeur 🌐 French ⚖ 996 KB

871 REAL-WORLD EFFICACY AND SAFETY OF TE

871 REAL-WORLD EFFICACY AND SAFETY OF TELAPREVIR IN COMBINATION WITH PEGINTERFERON alfa-2a AND RIBAVIRIN: INTERIM ANALYSIS FROM THE GERMAN NON-INTERVENTIONAL PAN STUDY

✍ Mauss, S.; Boeker, K.H.W.; Eisenbach, C.; Moeller, B.; Moog, G.; Lutz, T.; Nauma 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 72 KB

71 Peginterferon Alfa-2A (40KD) (PEGASYS

71 Peginterferon Alfa-2A (40KD) (PEGASYS®) in combination with ribavirin in African American and caucasian patients with chronic hepatitis C virus genotype 1: results of a multicenter study

✍ Lennox J. Jeffers; William Cassidy; Charles Howell; K. Rajender Reddy; Susan She 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 155 KB

187 Efficacy and safety of 22 weeks of m

187 Efficacy and safety of 22 weeks of maintenance therapy with peginterferon alfa-2A (40KD) (PEGASYS™) alone versus peginterferon alfa-2A (40KD) plus ribavirin(COPEGUS™) in naive patients with chronic hepatitis C and genotype 1 who responded to a 24-week course of peginterferon alfa-2A (40KD) plus ribavirin: an open, multicenter, randomized trial

✍ Jean-Pierre Bronowicki; Denis Ouzan; Arnaud Tzanck; Tarik Asselah; Herve Desmora 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 233 KB